MYC and the Control of Apoptosis (2024)

*Reference is also in this collection.

Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature318: 533–538 [PubMed] [Google Scholar]

Amanullah A, Liebermann DA, Hoffman B2000. p53-independent apoptosis associated with c-Myc-mediated block in myeloid cell differentiation. Oncogene19: 2967–2977 [PubMed] [Google Scholar]

Arhel NJ, Packham G, Townsend PA, Collard TJ, AM HZ, Sharp A, Cutress RI, Malik K, Hague A, Paraskeva C, et al. 2003. The retinoblastoma protein interacts with Bag-1 in human colonic adenoma and carcinoma derived cell lines. Int J Cancer106: 364–371 [PubMed] [Google Scholar]

Askew DS, Ashmun RA, Simmons BC, Cleveland JL1991. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene6: 1915–1922 [PubMed] [Google Scholar]

Berger R, Flexor M, Le Coniat M, Larsen CJ1996. Presence of three recurrent chromosomal reaarrangements, t(2;3) (p12;q37), del(8)(q24), and t(14;18), in an acute lymphoblastic leukemia. Cancer Genet Cytogenet86: 76–79 [PubMed] [Google Scholar]

Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I1993. Point mutations in the c-Myc transactivation domain are common in Burkitt’s lymphoma and mouse plasmacytomas. Nat Genet5: 56–61 [PubMed] [Google Scholar]

Boone DN, Qi Y, Li Z, Hann SR2011. Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci108: 632–637 [PMC free article] [PubMed] [Google Scholar]

Cato AC, Mink S2001. BAG-1 family of cochaperones in the modulation of nuclear receptor action. J Steroid Biochem Mol Biol78: 379–388 [PubMed] [Google Scholar]

Chang DW, Claassen GF, Hann SR, Cole MD2000. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol20: 4309–4319 [PMC free article] [PubMed] [Google Scholar]

Claveria C, Giovinazzo G, Sierra R, Torres M2013. Myc-driven endogenous cell competition in the early mammalian embryo. Nature500: 39–44 [PubMed] [Google Scholar]

de la Cova C, Abril M, Bellosta P, Gallant P, Johnston LA2004. Drosophila myc regulates organ size by inducing cell competition. Cell117: 107–116 [PubMed] [Google Scholar]

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell146: 904–917 [PMC free article] [PubMed] [Google Scholar]

de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW1998. E1A signaling to p53 involves the p19^ARF tumor suppressor. Genes Dev12: 2434–2442 [PMC free article] [PubMed] [Google Scholar]

Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev13: 2658–2669 [PMC free article] [PubMed] [Google Scholar]

Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hanco*ck DC1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell69: 119–128 [PubMed] [Google Scholar]

* Gabay M, Li Y, Felsher DW2014. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med 10.1101/cshperspect.a014407 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Gotz R, Kramer BW, Camarero G, Rapp UR2004. BAG-1 haplo-insufficiency impairs lung tumorigenesis. BMC Cancer4: 85. [PMC free article] [PubMed] [Google Scholar]

Hagiyama H, Adachi T, Yoshida T, Nomura T, Miyasaka N, Honjo T, Tsubata T1999. Signaling through the antigen receptor of B lymphocytes activates a p53-independent pathway of c-Myc-induced apoptosis. Oncogene18: 4091–4098 [PubMed] [Google Scholar]

Haupt Y, Rowan S, Shaulian E, Kazaz A, Vousden K, Oren M1997. p53 mediated apoptosis in HeLa cells: Transcription dependent and independent mechanisms. Leukemia11: 337–339 [PubMed] [Google Scholar]

Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW2005. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature436: 807–811 [PMC free article] [PubMed] [Google Scholar]

Jacobsen KA, Prasad VS, Sidman CL, Osmond DG1994. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of Eμ-myc transgenic mice. Blood84: 2784–2794 [PubMed] [Google Scholar]

* Johnston LA2014. Socializing with MYC: Cell competition in development and as a model for premalignant cancer. Cold Spring Harb Perspect Med 10.1101/cshperspect.a014274 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Johnston JM, Yu MT, Carroll WL1991. c-myc hypermutation is ongoing in endemic, but not all Burkitt’s lymphoma. Blood78: 2419–2425 [PubMed] [Google Scholar]

Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell91: 649–659 [PubMed] [Google Scholar]

Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci95: 8292–8297 [PMC free article] [PubMed] [Google Scholar]

Knezevich S, Ludkovski O, Salski C, Lestou V, Chhanabhai M, Lam W, Klasa R, Connors JM, Dyer MJ, Gascoyne RD, et al. 2005. Concurrent translocation of BCL-2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas. Leukemia19: 659–663 [PubMed] [Google Scholar]

Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ2004. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell6: 241–249 [PubMed] [Google Scholar]

* Levens D2013. Cellular MYCro economics: Balancing MYC function with MYC expression. Cold Spring Harb Perspect Med3: a014233. [PMC free article] [PubMed] [Google Scholar]

Levine AJ, Oren M2009. The first 30 years of p53: Growing ever more complex. Nat Rev Cancer9: 749–758 [PMC free article] [PubMed] [Google Scholar]

Lin J, Hutchinson L, Gaston SM, Raab G, Freeman MR2001. BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: A unique role for proHB-EGF in cell survival regulation. J Biol Chem276: 30127–30132 [PubMed] [Google Scholar]

Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA2012. Transcriptional amplification in tumor cells with elevated c-Myc. Cell151: 56–67 [PMC free article] [PubMed] [Google Scholar]

Lowe SW, Cepero E, Evan G2004. Intrinsic tumour suppression. Nature432: 307–315 [PubMed] [Google Scholar]

Luders J, Demand J, Papp O, Hohfeld J2000. Distinct isoforms of the cofactor BAG-1 differentially affect Hsc70 chaperone function. J Biol Chem275: 14817–14823 [PubMed] [Google Scholar]

Martin-Subero JI, Odero MD, Hernandez R, Cigudosa JC, Agirre X, Saez B, Sanz-Garcia E, Ardanaz MT, Novo FJ, Gascoyne RD, et al. 2005. Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL-2-positive germinal center B-cell lymphomas. Genes Chromosomes Cancer43: 414–423 [PubMed] [Google Scholar]

Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ III2011. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci108: 16669–16674 [PMC free article] [PubMed] [Google Scholar]

Mukhopadhyay S, Readling J, Cotter PD, Shrimpton AE, Sidhu JS2005. Transformation of follicular lymphoma to Burkitt-like lymphoma within a single lymph node. Human Pathology36: 571–575 [PubMed] [Google Scholar]

Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI2008. Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell14: 447–457 [PMC free article] [PubMed] [Google Scholar]

Neiman PE, Thomas SJ, Loring G1991. Induction of apoptosis during normal and neoplastic B-cell development in the bursa of Fabricius. Proc Natl Acad Sci88: 5857–5861 [PMC free article] [PubMed] [Google Scholar]

Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, et al. 2012. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell151: 68–79 [PMC free article] [PubMed] [Google Scholar]

Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM2012. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood120: 2843–2852 [PMC free article] [PubMed] [Google Scholar]

Ozdek A, Sarac S, Akyol MU, Sungur A, Yilmaz T2004. c-myc and bcl-2 expression in supraglottic squamous cell carcinoma of the larynx. Otolaryngol Head Neck Surg131: 77–83 [PubMed] [Google Scholar]

* Rahl PB, Young RA2014. MYC and transcription elongation. Cold Spring Harb Perspect Med4: a020990. [PMC free article] [PubMed] [Google Scholar]

* Roussel MF, Robinson GW2013. Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med3: 014308 [PMC free article] [PubMed] [Google Scholar]

Sakamuro D, Eviner V, Elliott KJ, Showe L, White E, Prendergast GC1995. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene11: 2411–2418 [PubMed] [Google Scholar]

* Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM2014. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med4: 014282 [PMC free article] [PubMed] [Google Scholar]

Sears R, Leone G, DeGregori J, Nevins JR1999. Ras enhances Myc protein stability. Mol Cell3: 169–179 [PubMed] [Google Scholar]

Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR1992. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science257: 212–214 [PubMed] [Google Scholar]

Strasser A, Harris AW, Bath ML, Cory S1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature348: 331–333 [PubMed] [Google Scholar]

Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC1995. Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity. Cell80: 279–284 [PubMed] [Google Scholar]

Topham CH, Taylor SS2013. Mitosis and apoptosis: How is the balance set?Curr Opin Cell Biol25: 780–785 [PubMed] [Google Scholar]

Trudel M, Lanoix J, Barisoni L, Blouin MJ, Desforges M, L’Italien C, D’Agati V1997. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent. J Exp Med186: 1873–1884 [PMC free article] [PubMed] [Google Scholar]

Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. 2008. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res68: 3421–3428 [PubMed] [Google Scholar]

Vassilev LT2004. Small-molecule antagonists of p53-MDM2 binding: Research tools and potential therapeutics. Cell Cycle3: 419–421 [PubMed] [Google Scholar]

Vita M, Henriksson M2006. The Myc oncoprotein as a therapeutic target for human cancer. Seminar Cancer Biol16: 318–330 [PubMed] [Google Scholar]

Wang HG, Takayama S, Rapp UR, Reed JC1996. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci93: 7063–7068 [PMC free article] [PubMed] [Google Scholar]

Wyllie AH, Rose KA, Morris RG, Steel CM, Foster E, Spandidos DA1987. Rodent fibroblast tumours expressing human myc and ras genes: Growth, metastasis and endogenous oncogene expression. Br J Cancer56: 251–259 [PMC free article] [PubMed] [Google Scholar]

Yano T, Sander CA, Clark HM, Dolezal MV, Jaffe ES, Raffeld M1993. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Oncogene8: 2741–2748 [PubMed] [Google Scholar]

Zhang XY, Pfeiffer HK, Mellert HS, Stanek TJ, Sussman RT, Kumari A, Yu D, Rigoutsos I, Thomas-Tikhonenko A, Seidel HE, et al. 2011. Inhibition of the single downstream target BAG-1 activates the latent apoptotic potential of MYC. Mol Cell Biol31: 5037–5045 [PMC free article] [PubMed] [Google Scholar]

Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev12: 2424–2433 [PMC free article] [PubMed] [Google Scholar]